Clinical trials
Phase 3 Primary Immunodeficiency Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Active, not recruiting | 4 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Octapharma | 7 |
| CSL Behring | 6 |
| Baxalta now part of Shire | 5 |
| Grifols Therapeutics LLC | 5 |
| Bio Products Laboratory | 4 |
| Takeda | 4 |
| CSL Limited | 3 |
| Kedrion S.p.A. | 3 |
| ADMA Biologics, Inc. | 2 |
| Azidus Brasil | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Immunodeficiency Diseases | 50 |
| Agammaglobulinemia | 5 |
| Common Variable Immunodeficiency | 5 |
| Immunologic Deficiency Syndromes | 4 |
| Hyper-IgM Immunodeficiency Syndrome | 3 |
| Wiskott-Aldrich Syndrome | 2 |
| Mucocutaneous Lymph Node Syndrome | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Severe Combined Immunodeficiency | 1 |
Trials
Showing 26 to 50 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.